NCT07136077 2026-02-27A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant ChemotherapyM.D. Anderson Cancer CenterPhase 2 Recruiting20 enrolled
NCT07413146 2026-02-17Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled TrialSun Yat-sen UniversityPhase NA Not yet recruiting100 enrolled
NCT06358430 2026-01-15Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)M.D. Anderson Cancer CenterPhase 1 Recruiting42 enrolled